Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28833769 | 0.78 | CNR2 (0.43) | CNR2 | |
| SCHEMBL27867020 | 0.77 | CNR2 (0.42) | CNR2MEN1KMT2A | |
| SCHEMBL28035571 | 0.76 | MEN1 (0.53) | CNR2PRKCAPRKCDMEN1KMT2A | |
| SCHEMBL4733699 | 0.76 | PRKCA (0.69) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4733378 | 0.76 | ESR1 (0.58) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL27710277 | 0.74 | ESR1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL21275726 | 0.74 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4453544 | 0.74 | LTA4H (0.47) | ESR1CNR2 | |
| SCHEMBL29208084 | 0.74 | NPSR1 (0.46) | MEN1KMT2A | |
| SCHEMBL9491739 | 0.74 | THRB (0.43) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178072-A1 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION | NATIONAL INSTITUTES OF HEALTH | 2011-07-21 | — | — | US | claimed |
| WO-2010011856-A2 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2010-01-28 | — | — | WO | claimed |
| US-5567437-A | MIXTURE OF ALKALI METAL CARBONATE AND ORGANIC ACID | LABORATORIES UPSA (FR) | 1996-10-22 | — | — | US | claimed |
| US-20110178072-A1 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION | NATIONAL INSTITUTES OF HEALTH | 2011-07-21 | — | — | US | disclosed |
| WO-2010011856-A2 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178072-A1 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION | TPMT, STS, MGMT | NSD2 476/4885ESR1 1749/4885AKR1C4 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.